Literature DB >> 21211583

Antigenic stability of H1N1 pandemic vaccines correlates with vaccine strain.

Aaron Farnsworth1, Terry D Cyr, Changgui Li, Junzhi Wang, Xuguang Li.   

Abstract

In 2009 a novel H1N1 influenza virus emerged and spread rapidly. Soon after vaccine lots were released, however, the shelf life was revised downward due to an unexpected decrease in HA potency. In this study, we found differences in both stability and antigenic content of two monovalent H1N1/2009 vaccine preparations. These appear to have arisen due to differences in the A/California/7/2009-like influenza strain used to prepare vaccine. Crown
Copyright © 2010. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21211583     DOI: 10.1016/j.vaccine.2010.12.120

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  16 in total

1.  Recombinant influenza A H3N2 viruses with mutations of HA transmembrane cysteines exhibited altered virological characteristics.

Authors:  Jianqiang Zhou; Shun Xu; Jun Ma; Wen Lei; Kang Liu; Qiliang Liu; Yida Ren; Chunyi Xue; Yongchang Cao
Journal:  Virus Genes       Date:  2013-11-23       Impact factor: 2.332

2.  Structural stability of influenza A(H1N1)pdm09 virus hemagglutinins.

Authors:  Hua Yang; Jessie C Chang; Zhu Guo; Paul J Carney; David A Shore; Ruben O Donis; Nancy J Cox; Julie M Villanueva; Alexander I Klimov; James Stevens
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

3.  Identification of H209 as Essential for pH 8-Triggered Receptor-Independent Syncytium Formation by S Protein of Mouse Hepatitis Virus A59.

Authors:  Pei Li; Yiwei Shan; Wangliang Zheng; Xiuyuan Ou; Dan Mi; Zhixia Mu; Kathryn V Holmes; Zhaohui Qian
Journal:  J Virol       Date:  2018-05-14       Impact factor: 5.103

4.  Design and Structure of an Engineered Disulfide-Stabilized Influenza Virus Hemagglutinin Trimer.

Authors:  Peter S Lee; Xueyong Zhu; Wenli Yu; Ian A Wilson
Journal:  J Virol       Date:  2015-04-29       Impact factor: 5.103

5.  Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant.

Authors:  David L Gordon; Dimitar Sajkov; Richard J Woodman; Yoshikazu Honda-Okubo; Manon M J Cox; Susanne Heinzel; Nikolai Petrovsky
Journal:  Vaccine       Date:  2012-06-17       Impact factor: 3.641

6.  Influenza virus M2 protein ion channel activity helps to maintain pandemic 2009 H1N1 virus hemagglutinin fusion competence during transport to the cell surface.

Authors:  Esmeralda Alvarado-Facundo; Yamei Gao; Rosa María Ribas-Aparicio; Alicia Jiménez-Alberto; Carol D Weiss; Wei Wang
Journal:  J Virol       Date:  2014-12-03       Impact factor: 5.103

7.  Intermonomer Interactions in Hemagglutinin Subunits HA1 and HA2 Affecting Hemagglutinin Stability and Influenza Virus Infectivity.

Authors:  Wei Wang; Christopher J DeFeo; Esmeralda Alvarado-Facundo; Russell Vassell; Carol D Weiss
Journal:  J Virol       Date:  2015-08-12       Impact factor: 5.103

8.  Endocine™, N3OA and N3OASq; three mucosal adjuvants that enhance the immune response to nasal influenza vaccination.

Authors:  Tina Falkeborn; Andreas Bråve; Marie Larsson; Britt Akerlind; Ulf Schröder; Jorma Hinkula
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

9.  Pandemic influenza vaccine: characterization of A/California/07/2009 (H1N1) recombinant hemagglutinin protein and insights into H1N1 antigen stability.

Authors:  Elena Feshchenko; David G Rhodes; Rachael Felberbaum; Clifton McPherson; Joseph A Rininger; Penny Post; Manon M J Cox
Journal:  BMC Biotechnol       Date:  2012-10-30       Impact factor: 2.563

10.  A novel synthetic receptor-based immunoassay for influenza vaccine quantification.

Authors:  Anwar M Hashem; Caroline Gravel; Aaron Farnsworth; Wei Zou; Michelle Lemieux; Kangwei Xu; Changgui Li; Junzhi Wang; Marie-France Goneau; Maria Merziotis; Runtao He; Michel Gilbert; Xuguang Li
Journal:  PLoS One       Date:  2013-02-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.